Latest News – PSNC Main site
Pharmaceutical Services Negotiating Committee
Class 2 Medicines Recall: Largactil 50mg/2ml solution for injection Aventis Pharma Ltd (trading as Sanofi)
Class 2 MHRA medicines recall – Largactil 50mg/2ml solution for injection Aventis Pharma Ltd (trading as Sanofi) PL 04425/0582 Betahistine dihydrochloride 16mg Tablets (Kent Pharmaceuticals Ltd) PL 30464/0020 Drug alert number: EL (20)A/56 Date issued: 26 November 2020 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 2 medicines recall for: Largactil...
Register now to use Real Time Exemption Checking (RTEC)
Real Time Exemption Checking (RTEC) allows pharmacy teams to digitally check if their patients are eligible for free NHS prescriptions because they hold specific exemptions. Pharmacies already using RTEC report that it saves staff time and because a patient that is found to be exempt via RTEC does not need to complete an exemption declaration...
PSNC seeks to address workload pressures during second wave
PSNC has today published an update on the action points that we have been discussing with the NHS and Government to address contractor workload and staffing pressures during the second wave of the COVID-19 pandemic. We have been highlighting the many operational pressures on pharmacy businesses throughout the pandemic and in recent months we have...
COVID-19 Second Wave – PSNC Negotiations Action List (November 2020)
This briefing outlines the scope of urgent discussions that are ongoing between PSNC, the Department of Health and Social Care (DHSC), and NHS England & NHS Improvement (NHSE&I) to ensure that community pharmacy teams have the support they need during the second wave of the COVID-19 pandemic. PSNC has some clear asks, some of which...
27 Products added to the Discount Not Deducted (DND) list
Following applications made by PSNC to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA), a further 27 new products will enter the list of ‘Drugs for which Discount is Not Deducted’ (DND) in Part II of the Drug Tariff from 1 December 2020. This follows the recent announcement...
Class 2 Medicines Recall: Betahistine dihydrochloride 8mg and 16mg tablets (Kent Pharmaceuticals Ltd)
Class 2 MHRA medicines recall – Betahistine dihydrochloride 8mg Tablets (Kent Pharmaceuticals Ltd) PL 30464/0019 Betahistine dihydrochloride 16mg Tablets (Kent Pharmaceuticals Ltd) PL 30464/0020 Drug alert number: EL (20)A/55 Date issued: 26 November 2020 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 2 medicines recall for: Betahistine dihydrochloride 8mg Tablets (Kent...
PSNC responds to Government Spending Review
Chancellor Rishi Sunak has today set out the Government’s spending plans for the remainder of 2020/21. HM Treasury is attempting to curb Government spending where possible due to the increasing amount of national debt that the response to the COVID-19 pandemic has created. However, in the midst of this healthcare crisis, NHS spending continues to...
Class 2 Medicines Recall: Abstral 200microgram sublingual tablets (Kyowa Kirin Ltd)
Class 2 MHRA medicines recall – Abstral 200microgram sublingual tablets (Kyowa Kirin Limited) PL 16508/0031 Drug alert number: EL (20)A/54 Date issued: 25 November 2020 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 2 medicines recall for: Abstral 200microgram sublingual tablets (Kyowa Kirin Limited) PL 16508/0031 Kyowa Kirin Limited is recalling...
November 2020 Price Concessions 2nd Update
The Department of Health and Social Care (DHSC) has today granted the following list of price concessions: Drug Pack Size Price Concession Desmopressin 10micrograms/dose nasal spray 60 dose £22.81 Docusate 100mg capsules 30 £3.20 Olmesartan medoxomil 40mg tablets 28 £3.46 Prochlorperazine 5mg tablets 28 £1.49 Senna 7.5mg tablets 60 £2.76 Sulfasalazine 500mg tablets 112 £6.88...
Becoming and maintaining HLP status to meet the new requirements
The Healthy Living Pharmacy (HLP) requirements will become part of the new Terms of Service for all pharmacies from 1st January 2021. NHS England and NHS Improvement’s (NHSE&I) regulations guidance, due to be published shortly, will set out the full requirements for compliance, but contractors can also find the details in our HLP website section. To support...
PharmaTimes: PharmaTimes Website RSS
PharmaTimes - The latest news in healthcare and life sciences - PharmaTimes Website RSS
NICE backs use of new treatment for multiple myeloma
Sanofi's Sarclisa gets the final green light for use by the NHS with funding from the CDF
Moderna signs deal with EU for 160 million COVID-19 vaccine doses
Delivery of vaccine doses to EU could begin by early 2021
Janssen's Tremfya approved for active psoriatic arthritis
Tremfya is a first-in-class treatment for the disease, shown to improve disease measures and quality of life
Mixed reaction to chancellor's spending review
Chancellor Rishi Sunak hands out extra £3 billion to NHS and £14.6 billion in funding for R&D
COVID-19 pandemic has emphasised existing health inequalities, research finds
New report conducted by Imperial College London researchers and Philips UK highlights issues within the NHS
BMS inks drug discovery deal with Schrödinger
Deal will focus on developing small molecules against a number of diseases
Over half of pharmacists report that COVID-19 has impacted their mental health
Survey from The Royal Pharmacy Society shows impact of pandemic on pharmacists’ mental health
GSK launches late-stage study of RSV vaccine in pregnant mothers
Shot will be evaluated in pregnant mothers and their newborn infants
Amgen hands back heart failure programme rights to Cytokinetics
Omecamtiv mecarbil and AMG 594 rights transitioned back to biotech
NICE backs Braftovi for BRAF-positive colorectal cancer
Positive recommendation follows initial rejection in September
FDA approves new dosing option for AZ’s Imfinzi
Less-frequent, fixed-dose use approved for two cancer indications
Sanofi’s meningococcal vaccine wins EU approval
MenQuadfi approved for vaccination in individuals 12 months of age or older
Annual pharma R&D spending in UK climbed 6.9% in 2019
R&D spending in the sector last year represents an eight-year high
Lilly to collaborate with Precision BioSciences on genome editing research
Lead programme will focus on developing therapies for Duchenne muscular dystrophy
Spending boost ‘welcome’ but more funding needed, says NHS Confed chief exec
Health leaders respond to reported £3bn funding boost
Every sector of the pharmaceutical market is represented under one roof, this year in Madrid. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.
Find out more: https://www.cphi.com/europe/